Paul B Rosenberg1, Lea T Drye2, Anton P Porsteinsson3, Bruce G Pollock4, D P Devanand5, Constantine Frangakis6, Zahinoor Ismail7, Christopher Marano1, Curtis L Meinert8, Jacobo E Mintzer9, Cynthia A Munro10, Gregory Pelton5, Peter V Rabins11, Lon S Schneider12, David M Shade13, Daniel Weintraub14, Jeffery Newell15, Jerome Yesavage16, Constantine G Lyketsos1. 1. Psychiatry and Behavioral Sciences,Division of Geriatric Psychiatry and Neuropsychiatry,Johns Hopkins School of Medicine,Johns Hopkins Bayview Medical Center,Baltimore,Maryland,USA. 2. Department of Epidemiology,Johns Hopkins Bloomberg School of Public Health,Maryland,USA. 3. Alzheimer's Disease Care,Research and Education Program (AD-CARE),University of Rochester School of Medicine and Dentistry,Rochester,New York,USA. 4. Campbell Institute,CAMH,University of Toronto,Toronto,Ontario,Canada. 5. Psychiatry and Neurology,Division of Geriatric Psychiatry,College of Physicians and Surgeons,Columbia University,New York,USA. 6. Department of Biostatistics,Johns Hopkins Bloomberg School of Public Health,Baltimore,Maryland,USA. 7. Psychiatry and Neurology,Hotchkiss Brain Institute,University of Calgary,Calgary,Alberta,Canada. 8. Epidemiology and Biostatistics,Johns Hopkins Bloomberg School of Public Health,Baltimore,Maryland,USA. 9. Clinical Biotechnology Research Institute,Roper St. Francis Healthcare,Charleston,South Carolina,USA. 10. Department of Psychiatry and Behavioral Sciences,Department of Neurology,Johns Hopkins Bayview and Johns Hopkins School of Medicine,Baltimore,Maryland,USA. 11. Psychiatry and Behavioral Sciences Johns Hopkins School of Medicine,Johns Hopkins Hospital,Baltimore,Maryland,USA. 12. Psychiatry,Neurology,and Gerontology,Keck School of Medicine,University of Southern California,Los Angeles,California,USA. 13. Departments of Medicine (Pulmonary) and Epidemiology (Center for Clinical Trials),Johns Hopkins Bloomberg School of Public Health,Baltimore,Maryland,USA. 14. Psychiatry and Neurology,Perelman School of Medicine at the University of Pennsylvania,Parkinson's Disease Research,Education and Clinical Center (PADRECC),Mental Illness Research,Education and Clinical Center (MIRECC),Philadelphia Veterans Affairs Medical Center,Philadelphia,Pennsylvania,USA. 15. Clinical Science,Culture and Mental Health Lab,University of Southern California,Los Angeles,California,USA. 16. Aging Clinical Research Center,Director Mental Illness Research Education and Clinical Center,VA Palo Alto Health Care System,Virginia,USA.
Abstract
BACKGROUND:Placebo responses raise significant challenges for the design of clinical trials. We report changes in agitation outcomes in the placebo arm of a recent trial of citalopram for agitation in Alzheimer's disease (CitAD). METHODS: In the CitAD study, all participants and caregivers received a psychosocial intervention and 92 were assigned to placebo for nine weeks. Outcomes included Neurobehavioral Rating Scale agitation subscale (NBRS-A), modified AD Cooperative Study-Clinical Global Impression of Change (CGIC), Cohen-Mansfield Agitation Inventory (CMAI), the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (NPI A/A) and Total (NPI-Total) and ADLs. Continuous outcomes were analyzed with mixed-effects modeling and dichotomous outcomes with logistic regression. RESULTS:Agitation outcomes improved over nine weeks: NBRS-A mean (SD) decreased from 7.8 (3.0) at baseline to 5.4 (3.2), CMAI from 28.7 (6.7) to 26.7 (7.4), NPI A/A from 8.0 (2.4) to 4.9 (3.8), and NPI-Total from 37.3 (17.7) to 28.4 (22.1). The proportion of CGI-C agitation responders ranged from 21 to 29% and was significantly different from zero. MMSE improved from 14.4 (6.9) to 15.7 (7.2) and ADLs similarly improved. Most of the improvement was observed by three weeks and was sustained through nine weeks. The major predictor of improvement in each agitation measure was a higher baseline score in that measure. CONCLUSIONS: We observed significant placebo response which may be due to regression to the mean, response to a psychosocial intervention, natural course of symptoms, or nonspecific benefits of participation in a trial.
RCT Entities:
BACKGROUND: Placebo responses raise significant challenges for the design of clinical trials. We report changes in agitation outcomes in the placebo arm of a recent trial of citalopram for agitation in Alzheimer's disease (CitAD). METHODS: In the CitAD study, all participants and caregivers received a psychosocial intervention and 92 were assigned to placebo for nine weeks. Outcomes included Neurobehavioral Rating Scale agitation subscale (NBRS-A), modified AD Cooperative Study-Clinical Global Impression of Change (CGIC), Cohen-Mansfield Agitation Inventory (CMAI), the Neuropsychiatric Inventory (NPI) Agitation/Aggression domain (NPI A/A) and Total (NPI-Total) and ADLs. Continuous outcomes were analyzed with mixed-effects modeling and dichotomous outcomes with logistic regression. RESULTS:Agitation outcomes improved over nine weeks: NBRS-A mean (SD) decreased from 7.8 (3.0) at baseline to 5.4 (3.2), CMAI from 28.7 (6.7) to 26.7 (7.4), NPI A/A from 8.0 (2.4) to 4.9 (3.8), and NPI-Total from 37.3 (17.7) to 28.4 (22.1). The proportion of CGI-C agitation responders ranged from 21 to 29% and was significantly different from zero. MMSE improved from 14.4 (6.9) to 15.7 (7.2) and ADLs similarly improved. Most of the improvement was observed by three weeks and was sustained through nine weeks. The major predictor of improvement in each agitation measure was a higher baseline score in that measure. CONCLUSIONS: We observed significant placebo response which may be due to regression to the mean, response to a psychosocial intervention, natural course of symptoms, or nonspecific benefits of participation in a trial.
Authors: Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: L S Schneider; J T Olin; R S Doody; C M Clark; J C Morris; B Reisberg; F A Schmitt; M Grundman; R G Thomas; S H Ferris Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: Barbara K Martin; Constantine E Frangakis; Paul B Rosenberg; Jacobo E Mintzer; Ira R Katz; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; George Niederehe; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2006-11 Impact factor: 4.105
Authors: Helen C Kales; Marcia Valenstein; H Myra Kim; John F McCarthy; Dara Ganoczy; Francesca Cunningham; Frederic C Blow Journal: Am J Psychiatry Date: 2007-10 Impact factor: 18.112
Authors: Martin Steinberg; Huibo Shao; Peter Zandi; Constantine G Lyketsos; Kathleen A Welsh-Bohmer; Maria C Norton; John C S Breitner; David C Steffens; Joann T Tschanz Journal: Int J Geriatr Psychiatry Date: 2008-02 Impact factor: 3.485
Authors: Alberto Costa; Thomas Bak; Paolo Caffarra; Carlo Caltagirone; Mathieu Ceccaldi; Fabienne Collette; Sebastian Crutch; Sergio Della Sala; Jean François Démonet; Bruno Dubois; Emrah Duzel; Peter Nestor; Sokratis G Papageorgiou; Eric Salmon; Sietske Sikkes; Pietro Tiraboschi; Wiesje M van der Flier; Pieter Jelle Visser; Stefano F Cappa Journal: Alzheimers Res Ther Date: 2017-04-17 Impact factor: 6.982
Authors: Luis Agüera-Ortiz; Ganesh M Babulal; Marie-Andrée Bruneau; Byron Creese; Fabrizia D'Antonio; Corinne E Fischer; Jennifer R Gatchel; Zahinoor Ismail; Sanjeev Kumar; William J McGeown; Moyra E Mortby; Nicolas A Nuñez; Fabricio F de Oliveira; Arturo X Pereiro; Ramit Ravona-Springer; Hillary J Rouse; Huali Wang; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Stephan Ehrhardt; Anton P Porsteinsson; Cynthia A Munro; Paul B Rosenberg; Bruce G Pollock; Davangere P Devanand; Jacobo Mintzer; Tarek K Rajji; Zahinoor Ismail; Lon S Schneider; Sheriza N Baksh; Lea T Drye; Dimitri Avramopoulos; David M Shade; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2019-10-03 Impact factor: 16.655